|Dr. John S. Kovach M.D.||Founder, Chairman, Chief Exec. Officer, Pres, CFO and Principal Accounting Officer||60k||N/A||80|
|Mr. Gil N. Schwartzberg Esq.||Consultant||N/A||N/A||N/A|
|Dr. Francis Johnson Ph.D.||Consultant||N/A||N/A||N/A|
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The companys primary focus is to develop various treatments for human cancers and other non-malignant diseases, including vascular diseases, such as heart attacks and strokes, and diabetes, as well as genetic diseases comprising Gauchers disease; and depression and post-traumatic stress syndrome. It develops protein phosphatase inhibitors that include LB-100 series of compounds; and histone deacetylase inhibitors, which comprises LB-200 series of compounds for the treatment of cancer, as well as in the prevention and treatment of neurodegenerative diseases, which are under various stages of pre-clinical and clinical developments. The company was founded in 2005 and is based in East Setauket, New York.
Lixte Biotechnology Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.